ASCO 2019 | DIRVA: intratumorally injected durvalumab for cervical cancer

Name: DIRVA: intratumorally injected durvalumab for cervical cancer
Uploaded: 2019-06-02T00:00:00Z
Duration: 1 min 30 s
Description: Gemma Kenter, MD, PhD, of the Amsterdam Centre for Oncological Gynaecology, Amsterdam, The Netherlands, tells about the DIRVA trial which investigated intratumorally injected durvalumab for the treatment of cervical cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Gemma Kenter • 2 Jun 2019

ASCO 2019

Cervical Cancer Gynecological Cancer Durvalumab

DIRVA

Gemma Kenter, MD, PhD, of the Amsterdam Centre for Oncological Gynaecology, Amsterdam, The Netherlands, tells about the DIRVA trial which investigated intratumorally injected durvalumab for the treatment of cervical cancer. This interview was recorded at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.